VYNE Therapeutics and Yarrow Bioscience announce merger agreement Dec 17, 2025 08:01AM
BTIG Downgrades VYNE Therapeutics (VYNE) to Neutral Jul 31, 2025 02:26AM
H.C. Wainwright Downgrades VYNE Therapeutics (VYNE) to Neutral Jul 30, 2025 10:19AM
VYNE Therapeutics phase 2b vitiligo trial fails primary endpoint Jul 30, 2025 08:01AM
VYNE Therapeutics (VYNE) Halted, News Pending Jul 30, 2025 07:52AM


Jul 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Jul 3, 2025 05:08AM BTIG Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Jul 2, 2025 07:45AM VYNE Therapeutics (VYNE) Provides Program Update on Oral BET inhibitor VYN202
May 8, 2025 04:28PM VYNE Therapeutics (VYNE) Misses Q1 EPS by 20c
Apr 28, 2025 07:10AM VYNE Therapeutics (VYNE) PT Lowered to $4.50 at H.C. Wainwright
Apr 25, 2025 08:02AM VYNE Therapeutics (VYNE) Reports Clinical Hold on VYN202 Program
Feb 20, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Feb 19, 2025 08:01AM VYNE Therapeutics (VYNE) Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Jan 7, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Dec 23, 2024 07:30AM VYNE Therapeutics (VYNE) Reports Positive Top-line Phase 1a MAD Data for VYN202
Nov 18, 2024 06:09AM BTIG Starts VYNE Therapeutics (VYNE) at Buy
Sep 13, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Sep 12, 2024 08:01AM VYNE Therapeutics (VYNE) Announces Positive Phase 1a SAD Data for VYN202
Aug 15, 2024 10:36AM TD Cowen Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Aug 15, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)
Aug 15, 2024 06:09AM VYNE Therapeutics (VYNE) Misses Q2 EPS by 22c
Jul 16, 2024 08:02AM VYNE Therapeutics (VYNE) Granted Composition of Matter Patent for VYN202
Jun 14, 2024 07:58AM H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)